Skip to main content
NCBI home page
Springer logoLink to Springer
. 2019 Sep 9;36(10):2927–2929. doi: 10.1007/s12325-019-01082-6

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Marilyn K Glassberg 1,✉, Steven D Nathan 2, Chin-Yu Lin 3, Elizabeth A Morgenthien 3, John L Stauffer 3, Willis Chou 4, Paul W Noble 5
PMCID: PMC6822818  PMID: 31502216

Correction to: Adv Ther 10.1007/s12325-019-01052-y

In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given below

Fig. 2.

Fig. 2

Open in a new tab

Time to first major adverse cardiac event–plus (a) and time to first bleeding event (b)

Articles from Advances in Therapy are provided here courtesy of Springer

RESOURCES